anbenitamab repodatecan

**Anbenitamab repodatecan (JSKN003)** is an antibody-drug conjugate (ADC) developed by site-specific conjugation of a topoisomerase I inhibitor payload to the Fc glycans of anbenitamab (KN026), a biparatopic anti-HER2 bispecific monoclonal antibody that binds two non-overlapping epitopes on HER2 (Receptor tyrosine-protein kinase erbB-2). This design results in a homogeneous ADC with a drug-to-antibody ratio (DAR) of approximately 4, enabling dual mechanisms of HER2 signal blockade, enhanced antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), HER2 receptor downregulation, and intracellular delivery of the payload to inhibit DNA topoisomerase I, leading to tumor cell death. Originally developed by Jiangsu Alphamab Biopharmaceuticals (Alphamab Oncology) in collaboration with CSPC Pharmaceutical Group, it targets HER2-expressing solid tumors, showing promising efficacy in heavily pretreated patients across HER2-positive, HER2-low, and even HER2-negative settings, with favorable safety including low rates of interstitial lung disease and no grade ≥3 events in early data. It has received Fast Track, Orphan Drug (US), and Breakthrough Therapy (China) designations and is in multiple Phase 3 trials.[1][2][4][19]

Other names

JSKN003JSKN-003JSKN 003